Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value
-
Shares outstanding
-
83.1M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
7.68M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$17.2M
-
Value change
-
+$4.11M
-
Put/Call ratio
-
0.27
-
Number of buys
-
28
-
Number of sells
-
-10
-
Price
-
$2.24
Significant Holders of Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) as of Q3 2024
53 filings reported holding CKPT - Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value as of Q3 2024.
Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.68M shares
of 83.1M outstanding shares and own 9.25% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (3.89M shares), VANGUARD GROUP INC (1.37M shares), GEODE CAPITAL MANAGEMENT, LLC (428K shares), BlackRock, Inc. (210K shares), PVG ASSET MANAGEMENT CORP (150K shares), WEALTH ENHANCEMENT ADVISORY SERVICES, LLC (130K shares), MORGAN STANLEY (104K shares), STATE STREET CORP (94.4K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (92.1K shares), and RENAISSANCE TECHNOLOGIES LLC (88.8K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.